Get the Stockscreener App
0.6791
51.14%
-0.7109
Pre-market:
.69
0.0109
+1.61%
Context Therapeutics Inc stock is traded at $0.6791, with a volume of 20.21M.
It is down -51.14% in the last 24 hours and down -68.56% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$1.39
Open:
$1.28
24h Volume:
20.21M
Relative Volume:
18.49
Market Cap:
$62.40M
Revenue:
-
Net Income/Loss:
$-40.23M
P/E Ratio:
-1.5885
EPS:
-0.4275
Net Cash Flow:
$-34.82M
1W Performance:
-60.29%
1M Performance:
-68.56%
6M Performance:
-39.90%
1Y Performance:
+7.90%
1-Day Range:
$0.63
$1.30
1-Week Range:
$0.63
$1.73
52-Week Range:
$0.56
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6791 | 62.40M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Initiated | Guggenheim | Buy |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Jan-08-25 | Initiated | JMP Securities | Mkt Outperform |
| Nov-25-24 | Initiated | D. Boral Capital | Buy |
| May-16-24 | Initiated | Piper Sandler | Overweight |
Context Therapeutics Inc Stock (CNTX) Latest News
CNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dip - Stocktwits
Small biotech Context Therapeutics reports 29% response rate in ovarian cancer study - MSN
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study - Benzinga
Context Therapeutics Announces Positive Inter - Moomoo
Context Therapeutics rises on interim Phase 1 ovarian cancer data - grafa.com
Context Therapeutics Reports Encouraging Phase 1 Results for CTIM-76 T Cell Engager in Platinum-Resistant Ovarian Cancer – Minichart - Minichart
CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in heavily pretreated PROC patients - TradingView
Context reports positive interim Phase 1 CTIM-76 data with 29% ORR in PROC, low CRS - TradingView
Context Therapeutics (NASDAQ: CNTX) shows early CTIM-76 activity in platinum-resistant ovarian cancer - Stock Titan
CNTX: CTIM-76 shows 29% response and strong safety in late-line platinum-resistant ovarian cancer - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 - The Manila Times
Context Therapeutics Announces Positive Interim Efficacy And Safety Results From Ongoing Phase 1 Clinical Trial For CTIM-76 - TradingView
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase ... - Caledonian Record
Context Therapeutics Announces Positive Interim Efficacy - GlobeNewswire
Context Therapeutics Grants New-Hire Equity Award Under Nasdaq Rule - MyChesCo
CNTX Q1 2026 Earnings: Narrower Loss Beats Estimates as Context Therapeutics Advances Clinical PipelinePost-Announcement Reaction - newsline.com
Context Therapeutics | 8-K: Current report - Moomoo
Analysts Offer Insights on Healthcare Companies: CVRx (CVRX) and Context Therapeutics (CNTX) - The Globe and Mail
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CNTX Q1 2026 Earnings: EPS Beat Amid Operational Progress; Stock DeclinesEarnings Stability Report - newsline.com
Context Therapeutics (CNTX) Sheds 13.8% as Stock Tests Key Support LevelLow Beta Factor - newsline.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
CNTX News | CONTEXT THERAPEUTICS INC (NASDAQ:CNTX) - ChartMill
Piper Sandler Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $7 - Moomoo
- The Legal Advocate
Context Therapeutics (CNTX) Edges Higher, Tests Resistance Near $3.00Impulse Wave - The Legal Advocate
Gyre Therapeutics (GYRE) Gains Momentum: Price Nears Key Resistance at $6.21Equal Weight ETF - The Legal Advocate
Context Therapeutics (CNTX) Holds Near Support as Biotech Sector Faces HeadwindsVolume Rate Change - The Legal Advocate
CNTX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive SurpriseRevenue Estimate Trend - The Legal Advocate
Context Therapeutics Gains 34%, Insider Trades Reap Benefit - 富途牛牛
CNTX Q1 2026 Earnings: Narrower Loss Surprises, Shares Advance Over 13%Estimate Accuracy - The Legal Advocate
Context Therapeutics to Present at the Jefferies Global Healthcare Conference - The Manila Times
Context Therapeutics (CNTX) Surges Over 8% Amid Renewed Buying Interest Above Key SupportGamma Squeeze - The Legal Advocate
Context Therapeutics (CNTX) Gets a Buy from Piper Sandler - The Globe and Mail
CNTX Q1 2026 Earnings: Context Therapeutics Beats EPS Estimates with Narrower-Than-Expected LossGAAP Earnings Report - The Legal Advocate
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Raises Target Price to $8 - Moomoo
Context Therapeutics Decline Means Insider Profits Down To US$237k - simplywall.st
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 - Sahm
Why Is Context Therapeutics Inc. (CNTX) Stock Down Today? - Meyka
Why Is Context Therapeutics Inc. (CNTX) Stock Up Today? - Meyka
Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal - Moomoo
Context Therapeutics Secures Full Rights to CT-202 from BioAtla with License Buyout, Phase 1 Trial Planned for Q3 2026 - Minichart
Context Therapeutics Secures Full Rights to Antibody Assets - TipRanks
Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free - TradingView
Context Therapeutics enters into license agreement amendment with BioAtla for CT-202 - marketscreener.com
Context Therapeutics Inc. Announces Amendment to License Agreement for CT-202, Securing Full Economic Rights - Quiver Quantitative
Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license - Stock Titan
Context Therapeutics Advances Cancer Drug Pipeline Toward Data Readouts - MyChesCo
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):